Compare CIK & BHST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | CIK | BHST |
|---|---|---|
| Founded | 1987 | 2007 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.7M | 162.2M |
| IPO Year | N/A | N/A |
| Metric | CIK | BHST |
|---|---|---|
| Price | $2.82 | $6.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | ★ 115.4K | 107.0K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 9.03% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $32,720,000.00 |
| Revenue This Year | N/A | $116.40 |
| Revenue Next Year | N/A | $55.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 45.88 |
| 52 Week Low | $2.50 | $4.72 |
| 52 Week High | $3.19 | $12.80 |
| Indicator | CIK | BHST |
|---|---|---|
| Relative Strength Index (RSI) | 46.16 | 38.86 |
| Support Level | $2.81 | $6.25 |
| Resistance Level | $2.85 | $7.20 |
| Average True Range (ATR) | 0.03 | 0.72 |
| MACD | 0.01 | 0.09 |
| Stochastic Oscillator | 68.18 | 24.49 |
Credit Suisse Asset Mgmt Income Fund Inc is a closed-end management investment company. The investment objective of the fund is to provide current income consistent with the preservation of capital. Credit Suisse serves as an investment adviser for the fund. Asset Management offers a wide range of investment products and functions across asset classes and investment styles. The division manages various regional portfolios, mutual funds, and other investment vehicles for governments, institutions, corporations and individuals.
BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. This company is the industrial large-scale plant cell growth technology capable of directly and constantly producing active plant ingredients without the necessity to grow the plant itself. The company is focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinical therapeutic solutions, within two business verticals - nutraceutical health and wellness products such as dietary supplements, and the development of plant cell-based Active Pharmaceutical Ingredients (APIs) that focus on specific medical indications.